Table 4.

Variants associated with transient ITP, compared with chronic ITP

Transient ITP (self-limiting or IVIg-responsive) TIKI (N = 131)Chronic ITP (CINKID & TIKI; N = 43)PP (FDR adjusted)OR (95% CI)
0123401234
CNV
 CNR10 (0)4 (3)118 (90)9 (7)0 (0)0 (0)7 (16)33 (77)3 (7)0 (0).011.116.2 (1.8-24.7)*
 CNR20 (0)0 (0)126 (96)5 (4)0 (0)0 (0)1 (2)42 (98)0 (0)0 (0).09.45
 CNR30 (0)0 (0)131 (100)0 (0)0 (0)0 (0)0 (0)43 (100)0 (0)0 (0)NDND
Alleles
 FCGR2A*27W88 (67)39 (30)4 (3)0 (0)0 (0)37 (86)5 (12)1 (2)0 (0)0 (0).041.373.3 (1.3-10.1)
 FCGR2A*131H27 (21)68 (52)36 (27)0 (0)0 (0)11 (26)18 (42)14 (33)0 (0)0 (0).50.37
 FCGR2B*232T98 (75)30 (23)3 (2)0 (0)0 (0)31 (72)10 (23)2 (5)0 (0)0 (0).721.0
 FCGR2C*ORF81 (62)48 (37)2 (2)0 (0)0 (0)38 (88)5 (12)0 (0)0 (0)0 (0).002.0224.7 (1.9-14.3)
 FCGR2C*ncORF125 (95)3 (2)3 (2)0 (0)0 (0)38 (88)2 (5)3 (7)0 (0)0 (0).19.57
 FCGR3A*158V46 (35)63 (48)22 (17)0 (0)0 (0)13 (30)22 (51)8 (19)0 (0)0 (0).871.0
 FCGR3B*NA211 (8)66 (50)54 (42)0 (0)0 (0)9 (21)18 (42)16 (37)0 (0)0 (0).10.45
 FCGR3B*SH128 (98)3 (2)0 (0)0 (0)0 (0)39 (91)4 (9)0 (0)0 (0)0 (0).06.37
 FCGR2 promoter 2B.492 (70)39 (30)0 (0)0 (0)0 (0)37 (86)6 (14)0 (0)0 (0)0 (0).045.372.6 (1.1-7.3)
  • Data are n (% of cohort). Bold values denote statistically significant P values. Chronic ITP was defined as absence of complete response (platelet count >100 × 109/L) 12 months after diagnosis. Transient ITP was defined as spontaneous recovery or a favorable response to IVIg 3 months after diagnosis. Patients from the TIKI trial with persistent ITP (recovery between 3 and 12 months) were excluded.

  • * OR given for chronic ITP.

  • OR given for comparison of 27Q/W vs 27Q/W in association with transient ITP.

  • OR given for presence of 1 or 2 copies vs absence of the variant in association with transient ITP.